Ultomiris (ravulizumab) has been approved in Japan as the first and only long-acting C5 complement inhibitor for the treatment of adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).
Earlier this month, the European Commission approved Ultomiris, and regulatory submissions are currently under review with multiple health authorities elsewhere, including in the USA.
"An innovative long-acting treatment option that has the potential to eliminate relapses with convenient dosing every eight weeks"The drug has been developed by Alexion, a subsidiary of Anglo-Swedish pharma major AstraZeneca (LSE: AZN), as a follow-on from Soliris (eculizumab), its previously-approved treatment for NMOSD.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze